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Introduction and highlights  
The number of patients with refractory angina without 
revascularization options is increasing. The prognosis and the quality 
of life in these patients is poor and maximal medical therapy is not 
enough for symptoms relieve.  According to the last American College 
of Cardiology/American Heart Association (ACC/AHA) guidelines on 
the management of chronic stable angina, the objective of the 
treatment should be the resolution of angina attacks, the reduction of 
the numbers of hospitalizations and the carrying out of normal daily 
activities without symptoms [1-6]. 
Extracorporeal Shockwave Myocardial Revascularization 
therapy (ESMR) is a non-invasive treatment and several studies have 
demonstrated its safety and its efficacy in patients with refractory 
angina (RA) to improve myocardial perfusion and exercise capacity 
reducing symptoms by the application shockwaves (SW) on the culprit 
ischemic area of the heart under echocardiographic guidance [7-26]. 
Shockwaves consist of low-intensive acoustic energy artificially 
generated by discharging of a high voltage spark under water by a 
generator designed to address the clinical anatomical requirements of 
the chest cavity. Several treatment sessions are required. The aim of 
this treatment is former to induce vasodilatation and latter to induce 
neovascularization from the healthy area to the ischemic area [27-37]. 
But, actually, there are no data about the safety of ESMR in patients 
with a mechanical prosthetic valve. 
We would report about a 64-year-old man with coronary artery disease 
(CAD) and refractory angina pectoris despite maximally tolerated 
medical therapy and after percutaneous coronary intervention (PCI) 
and with a prosthetic aortic valve and aortic tube. 
The patient received extracorporeal shockwave myocardial 
revascularization therapy without any complication during or after 
treatment. 
1. Case presentation 
                64-years-old male patient with coronary artery disease 
debuted in 2002 with an anterior ST-elevation myocardial infarction 
(STEMI) treated by percutaneous coronary intervention (PCI) on 
medial left anterior descending artery (LAD) with implantation of a 
Bare Metal Stent (BMS). 
In 2004, for the evidence of the stenosis of the bicuspid aortic valve 
and an ascending aorta aneurysm, substitution of the aortic valve and 
the ascending aorta with a mechanical valve attached to a Dacron tube 





In 2011, for new evidence of stress angina, PCI with a drug eluting stent 
(DES) implantation of the proximal RCA was performed. 
In 2013, for stress angina recurrence, a myocardial single-photon emission 
computed tomography (SPECT) with pharmacological stress 
(Dipyridamole) was performed, with the evidence of modest inducible 
ischemia in inferior cardiac wall (SRS 3, SSS 9, SDS 6), without CAD 
progression at the coronary angiography. 
For this reason, in 2014, we decided to treat the patient with shockwaves 
therapy. 
2. ESMR protocol 
We locate the area to treat by documenting inducible ischemia at the stress 
myocardial SPECT. The ESMR were applicated with a commercially 
available cardiac shock wave generator system (Cardiospect TM, 
Medispec, Germantown, MD) under echocardiographic guidance (Figure 
1.A and B): through a cardiac ultrasound imaging system, we look at this 
area and these measurements are calibrated into the shockwave applicator 
head to ensure the position of the focal treatment zone, so using an 
electrocardiographic R-wave gating, shockwaves are delivered through the 
applicator to the sub-endocardial myocardium of the ischemic area. We 
applied a low energy of shockwaves (0.09 mJ/mm2, ≈10% of the energy 
for the lithotripsy treatment). 
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Figure 1. The methodology of cardiac shock wave therapy. 
A. Shock wave generator system (Medispec, Germantown, MD, 
USA). 
B. Shock wave focal zone alignment: Position of the sub-segment on 
the 2-dimensional image determined by X and Y coordinates. The 
shockwave applicator position is identically adjusted along. X- and Y-
axes corresponding to the X and Y coordinates of the ultrasound 
image.  
                   The ischemic area was divided into 3 zones, corresponding 
to the three sessions of treatments. The treatment was divided into 
three sessions with 3 treatments for week every 4 weeks. 100 pulses 
gated by R wave trigger was performed for each target spotted (up to a 
total of 1000 pulses) at each individual session. Each session lasted 
about 20 minutes. During the treatment, symptoms and vital signs 
were continuously monitored. 
3. Echocardiographic prosthesis control 
A regular echocardiographic follow-up was performed, 
without evidence of malfunction or complications about the 
mechanical prosthetic aortic valve and tube: 
In 2013, before ESMR therapy, prosthetic valve had a normal function 
and position, pressure gradient (PG) was 13/6 mmHg, Aortic Valve 
Area (AVA) measured by Velocity Time integral (VTi) was 2.3 cm2 
and Doppler Velocity index (DVi) was 0.56. Prosthetic tub was 
regular without dehiscence. 
-In 2014 prosthetic valve had a normal function and position, PG was 
15/8 mmHg, V max was 2 m/sec and DVi was 0.30. Prosthetic tub 
was regular without dehiscence (Figure 2). 
 





Last echocardiographic study was performed in January 2018 and showed 
a prosthetic valve with a normal function and position, PG was 12/8 
mmHg, V max was 1.7 m/sec. Prosthetic tub was regular without 
dehiscence (Figure 3). 
 
Figure 3. Echocardiography performed in 2018, three years after ESMR. 
4. Conclusion                               
In conclusion, we treated by ESMR a patient with refractory angina and 
with mechanical prosthetic aortic valve and tube, without any sign of 
complication or malfunction of the cardiac device in acute or in further 
years. 
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